The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Trimel Announces Issuance of Additional Patent Covering NATESTO™

27-Nov-2014 | Source : | Visits : 7037
TORONTO, ONTARIO - Trimel Pharmaceuticals Corporation announced in a press release that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO™ and its proprietary nasal gel technology. Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO™. The Orange Book is the FDA's database of Approved Drug Products with Therapeutic Equivalence Evaluations.
This patent further enhances the patent protection available to NATESTO™ and should represent the fourth Orange Book-listed patent with claims covering the product until 2024. 

"The issuance of this patent provides additional evidence of the innovative and differentiated value of NATESTO™", said Tom Rossi, President and Chief Executive Officer of Trimel. "This patent further strengthens our intellectual property position and provides further protection for this important product in Trimel's portfolio."

Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health, and respiratory medicine. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, has been approved for sale in the United States by the FDA and is licensed to an affiliate of Endo International plc for commercialization. For more information, please visit 

Related Articles